UKI-1 (UKI-1C) (Synonyms: UKI-1C) |
| Catalog No.GC32119 |
UKI-1 (UKI-1C) (UKI-1 (UKI-1C)C) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 (UKI-1C) is also a low molecular weight serine protease inhibitor. UKI-1 (UKI-1C) is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 220355-63-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UKI-1 is a novel synthetic inhibitor of the urokinase-type plasminogen activator system. It can also inhibits the invasive capacity of carcinoma cells. (Ki=0.41 μM)In vitro : A decrease of tumor cell invasion by up to 50% was achieved in both models with the SCCHN line FaDu and the cervical carcinoma line HeLa after treatment with UK1.
[1]. Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. [2]. Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301(2):465-75.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *